Faculty Information - HIRAO Maki | Daito Bunka University

（Last updated : 2024-09-10 22:36:13）

Visruth.jpg not found

HIRAO Maki

Department Daito Bunka University Faculty of Sports and Health Science Department of Health Science

Job Professor

E-Mail Address

Grants-in-Aid for Scientific Researcher number
10902158

researchmap Researcher code
R000034596

Present specialized field
Sports Medicine, Clinical pharmacy

Academic background
1.	1990/10～1993/06	Dimond High School, Anchorage, Alaska, U.S.A. Graduated
2.	1994/05～1997/05	Major in Biochemistry College of Liberal Arts, Tufts University, Medford, Massachusetts, U.S.A., Graduated
3.	1998/06～2003/12	Doctorial Program in Biomolecular Structure and Design, University of Washington, Seattle, Washington, U.S.A., Finished
4.	2005/04～2009/03	School of Medicine Hokkaido University Graduated Doctor of Medicine

Business career
1.	1996/09 ～ 1996/11	Teaching Assistant Tufts University, Cells and Organisms Laboratory,
2.	1998/06 ～ 2003/12	Research Assistant University of Washington/Fred Hutchinson Cancer Research Center, Clinical Research Division and Public Health Sciences Division,
3.	2000/03 ～ 2000/06	Teaching Assistant University of Washington, Cell Biology, Molecular Biology of Disease,
4.	2009/04 ～ 2011/03	Tokyo Saiseikai Central Hospital
5.	2011/04 ～ 2015/03	Tokyo Saiseikai Central Hospital Department of Medicine
Display All（6）

Belonging society
1.	2013/02 ～	International Myeloma Society
2.	2024/05 ～	Japan Society of Golf Sciences

Books and Papers
1.	Papers	Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells Pharmaceuticals 16,pp.1367-1382 (Co-authored) 2023/09
2.	Papers	Factors Associated with Refraining from Health Checkups during the COVID-19 Pandemic in Japan Healthcare 11 (17),pp.2385-2397 (Co-authored) 2023/08
3.	Papers	Novel Aldosterone Antagonists in Hypertension and Diabetic Kidney Disease Japanese Pharmacology & Therapeutics,pp.1071-1087 (Co-authored) 2023/07
4.	Papers	GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c-MET tyrosine kinase Cancer medicine 12 (8),pp.9749-9759 (Co-authored) 2023/02
5.	Papers	Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan. Scientific reports 12 (1),pp.17139 (Co-authored) 2022/10
Display All（20）

Academic conference presentation
1.	2024/05	Result of the questionnaire survey on diversity, equity, and inclusion (DE & I) by the diversity promotion committee of the Japanese Society of Myeloma
2.	2020/07	A Hereditary bleeding disorder caused by a novel homozygous mutation of thrombomodulin gene (The Congress of the International Society on Thrombosis and Hemostasis)
3.	2018/12	Immunomodulatory Effects of Proteasome Inhibitors in Multiple Myeloma (the 60th American Society of Hematology Annual Meeting and Exposition Annual Meeting)
4.	2018/07	Identification of clonal evolution of CSF3R-mutated chronic neutrophilic leukemia using mutational screens of SETBP1, ASXL1 and SRSF2 (the 9th JSH International Symposium)
5.	2003/03	Inhibitors of Sir2p: evaluation of Splitomicin analogues (the 225th American Chemical Society National Meeting)
Display All（6）

Research topic, funded research, and department laboratory expense
1.	1996/06 ～ 1996/08	Howard Hughes Medical Institute Undergraduate Research Fellows (Tufts University), Localization of Allin Lyase mRNA in the Garlic Clove by in situ Hybridization with Digoxigenin-Riboprobes Joint Research inside the organization